Allianz Asset Management GmbH Buys 203,834 Shares of Integra LifeSciences Holdings Corporation $IART

Allianz Asset Management GmbH grew its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 88.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 433,738 shares of the life sciences company’s stock after buying an additional 203,834 shares during the quarter. Allianz Asset Management GmbH’s holdings in Integra LifeSciences were worth $6,215,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after buying an additional 913 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Integra LifeSciences by 205.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after acquiring an additional 2,108 shares during the last quarter. Osaic Holdings Inc. raised its position in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. AlphaQuest LLC bought a new stake in Integra LifeSciences during the second quarter worth about $73,000. Finally, EMC Capital Management bought a new stake in Integra LifeSciences during the second quarter worth about $75,000. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on IART shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Citigroup reduced their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research report on Friday, October 31st. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Truist Financial restated a “hold” rating and issued a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $15.00.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $10.93 on Tuesday. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.14 and a quick ratio of 1.80. Integra LifeSciences Holdings Corporation has a one year low of $10.65 and a one year high of $25.95. The business’s 50 day simple moving average is $12.46 and its two-hundred day simple moving average is $13.32. The stock has a market capitalization of $851.34 million, a P/E ratio of -1.69 and a beta of 1.04.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.